HIV Disclosure and Medication Adherence, a Pilot Study (RSAD-VIH-11)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Centre Hospitalier Universitaire Vaudois
Swiss HIV Cohort Study
Information provided by (Responsible Party):
Marie Schneider, Policlinique Médicale Universitaire
ClinicalTrials.gov Identifier:
NCT01621412
First received: May 31, 2012
Last updated: June 13, 2012
Last verified: June 2012
  Purpose

The investigators believe that disclosure of HIV status could influence medication adherence. If disclosure leads to social support, adherence could be improved. This study purpose is to assess correlation between disclosure and medication adherence, and to describe people whose HIV status has been disclosed to.


Condition
HIV Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: HIV Disclosure and Medication Adherence, a Pilot Study

Resource links provided by NLM:


Further study details as provided by Policlinique Médicale Universitaire:

Primary Outcome Measures:
  • Patient Adherence [ Time Frame: 30 days before survey ] [ Designated as safety issue: No ]
    Electronic monitoring of adherence during 30 days before survey


Secondary Outcome Measures:
  • Patient Adherence [ Time Frame: 90 days before survey ] [ Designated as safety issue: No ]
    Electronic monitoring of adherence during 90 days before survey


Estimated Enrollment: 120
Study Start Date: April 2012
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Detailed Description:

Pharmacists administer a questionnaire to each consecutive subject taking part in the adherence-enhancing program at the pharmacy of the Department of Ambulatory Care And Community Medicine in Lausanne. This questionnaire assesses disclosure, response to disclosure, and living situation.

Adherence is measured by electronic monitoring and pill count.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients enrolled in the adherence-enhancing program at ther pharmacy of Department of Ambulatory Care and Community Medicine in Lausanne

Criteria

Inclusion Criteria:

  • HIV Infection
  • Enrolled in the adherence-enhancing program

Exclusion Criteria:

  • Inclusion visit
  • Not french or english speaker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01621412

Locations
Switzerland
Policlinique Médicale Universitaire
Lausanne, Vaud, Switzerland, 1011
Sponsors and Collaborators
Policlinique Médicale Universitaire
Centre Hospitalier Universitaire Vaudois
Swiss HIV Cohort Study
Investigators
Principal Investigator: Marie-Paule Schneider, PhD Policlinique Médicale Universitaire
Principal Investigator: Aurélie Gertsch, PhD-Student Policlinique Médicale Universitaire
Study Chair: Olivier Bugnon, Professor Policlinique Médicale Universitaire
Study Chair: Matthias Cavassini, MD Centre Hospitalier Universitaire Vaudois
  More Information

No publications provided

Responsible Party: Marie Schneider, Pharmacist, PhD, Policlinique Médicale Universitaire
ClinicalTrials.gov Identifier: NCT01621412     History of Changes
Other Study ID Numbers: RSAD-VIH-2011
Study First Received: May 31, 2012
Last Updated: June 13, 2012
Health Authority: Switzerland: Ethikkommission

Keywords provided by Policlinique Médicale Universitaire:
Medication Adherence
HIV infection
Disclosure

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on August 27, 2014